Payment overview · 2025
General Payments
$603.37
31 reported records · 16 companies
Healthcare provider profile · identity verified
Herman Mathias, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · HEMET, CA · NPI 1487767265
Verified facts
What the public records show
CMS Open Payments records show Herman Mathias, M.D received $603.37 in general payments during 2025 across 31 reported records.
Lundbeck LLC accounted for 11.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Prolia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lundbeck LLC | Unresolved — no canonical attribution shown | $70.36 | 11.7% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $62.44 | 10.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $61.21 | 10.1% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $61.00 | 10.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $57.03 | 9.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.41 | 7.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $38.81 | 6.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.85 | 5.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.14 | 5.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $27.95 | 4.6% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $23.47 | 3.9% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $21.74 | 3.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.22 | 3.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.09 | 3.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.12 | 2.8% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $15.53 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $603.37 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $88.45 | 6 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $62.44 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $61.21 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $61.21 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $61.00 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $57.03 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $38.81 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.85 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $30.14 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.71 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $27.95 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $27.95 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.11 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.11 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $23.47 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $21.74 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $15.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
20 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 471 | 144 |
| Atorvastatin Calcium | Atorvastatin Calcium | 371 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 316 | 80 |
| Allopurinol | Allopurinol | 264 | 66 |
| Losartan Potassium | Losartan Potassium | 234 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 201 | 71 |
| Metformin Hcl | Metformin Hcl | 200 | 55 |
| Furosemide | Furosemide | 169 | 40 |
| Lisinopril | Lisinopril | 168 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 168 | 52 |
| Tramadol Hcl | Tramadol Hcl | 168 | 45 |
| Omeprazole | Omeprazole | 153 | 48 |
| Gabapentin | Gabapentin | 150 | 38 |
| Simvastatin | Simvastatin | 144 | 34 |
| Alprazolam | Alprazolam | 127 | 47 |
| Eliquis | Apixaban | 122 | 28 |
| Lorazepam | Lorazepam | 104 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 101 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 99 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 97 | 28 |
| Ozempic | Semaglutide | 93 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 26 |
| Potassium Chloride | Potassium Chloride | 90 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 82 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 77 | 24 |
| Carvedilol | Carvedilol | 75 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 20 |
| Azithromycin | Azithromycin | 71 | 55 |
| Prednisone | Prednisone | 71 | 30 |
| Sertraline Hcl | Sertraline Hcl | 67 | 23 |
| Trazodone Hcl | Trazodone Hcl | 66 | 22 |
| Donepezil Hcl | Donepezil Hcl | 63 | 13 |
| Mirtazapine | Mirtazapine | 63 | 16 |
| Atenolol | Atenolol | 61 | 21 |
| Xarelto | Rivaroxaban | 60 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 14 |
| Repatha Sureclick | Evolocumab | 57 | 16 |
| Famotidine | Famotidine | 52 | 15 |
| Baclofen | Baclofen | 50 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | suppressed |
| Clonazepam | Clonazepam | 46 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 13 |
| Levetiracetam | Levetiracetam | 46 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 43 |
| Spironolactone | Spironolactone | 45 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 44 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | 20 |
| Metformin Hcl Er | Metformin Hcl | 41 | 15 |
| Levemir Flexpen | Insulin Detemir | 38 | suppressed |
| Finasteride | Finasteride | 36 | 14 |
| Lovastatin | Lovastatin | 36 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | 12 |
| Glipizide | Glipizide | 34 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 34 | 13 |
| Digoxin | Digoxin | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Temazepam | Temazepam | 29 | 14 |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | 16 |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Repatha Syringe | Evolocumab | 27 | suppressed |
| Ibuprofen | Ibuprofen | 26 | 13 |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Lidocaine | Lidocaine | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Prolia | Denosumab | 20 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Teriflunomide | Teriflunomide | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $603.37 · 31 records | Lundbeck LLC | ACCRUFER, AIRSUPRA, CAPLYTA, CAPVAXIVE, FREESTYLE LIBRE 3, GARDASIL 9, INGREZZA, Korlym, LOREEV XR, MOUNJARO, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, XIFAXAN, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error